Cyclosporine versus everolimus: Effects on the glomerulus

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages 535-540

  Baas, Marije C ^a   Kers, Jesper ^a   Florquin, Sandrine ^a   De Fijter, Johan W ^b   Homan van der Heide, Jaap J ^c   Van den Bergh Weerman, Marius A ^a   Ten Berge, Ineke J M ^a   Bemelman, Frederike J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Everolimus; Glomerular basement membrane; mTOR inhibitor; Podocytes; Proteinuria

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTRON MICROSCOPY; FEMALE; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EVEROLIMUS; GLOMERULAR BASEMENT MEMBRANE; MTOR INHIBITOR; PODOCYTES; PROTEINURIA;

ADULT; AGED; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SIROLIMUS; YOUNG ADULT;

EID: 84881546173     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12144     Document Type: Article

References (26)

1. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009: 4: 481.
2. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004: 4: 1869.
3. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005: 80: 1198.
4. Buchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007: 7: 2522.
5. Stephany BR, Augustine JJ, Krishnamurthi V et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006: 82: 368.
6. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007: 2: 326.
7. Alperovich G, Rama I, Lloberas N et al. New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 2007: 16: 18.
8. Bonegio RG, Fuhro R, Wang Z et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005: 16: 2063.
9. Lloberas N, Cruzado JM, Franquesa M et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006: 17: 1395.
10. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006: 1: 109.
11. Vollenbroker B, George B, Wolfgart M, Saleem MA, Pavenstadt H, Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009: 296: F418.
12. Bertoni E, Bruschi M, Candiano G et al. Posttransplant proteinuria associated with everolimus. Transplant Proc 2009: 41: 1216.
13. Inza A, Balda S, Alvarez E, Zarraga S, Gainza FJ, Lampreabe I. Conversion to everolimus in kidney transplant recipients with decreased renal function. Transplant Proc 2009: 41: 2134.
14. Ayala M, Morales J, Fierro A, Herzog C, Calabran L, Buckel E. Metabolic changes following conversion from an anticalcineurin-based therapy to an everolimus-based one: a single-center experience. Transplant Proc 2008: 40: 3265.
15. Holdaas H, Bentdal O, Pfeffer P, Mjornstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008: 22: 366.
16. Neau-Cransac M, Moreau K, Deminiere C, Merville P, Saric J. Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy. Transpl Int 2009: 22: 586.
17. Bemelman FJ, De Maar EF, Press RR et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009: 88: 421.
18. Van Den Berg JG, Van Den Bergh Weerman MA, Assmann KJ, Weening JJ, Florquin S. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004: 66: 1901.
19. Gundersen HJ, Seefeldt T, Osterby R. Glomerular epithelial foot processes in normal man and rats. Distribution of true width and its intra- and inter-individual variation. Cell Tissue Res 1980: 205: 147.
20. Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011: 79: 502.
21. Yang Y, Wang J, Qin L et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007: 27: 495.
22. Letavernier E, Bruneval P, Vandermeersch S et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009: 24: 630.
23. Saurina A, Campistol JM, Piera C et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006: 21: 488.
24. Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008: 14: 931.
25. Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006: 6: 429.
26. Oroszlan M, Bieri M, Ligeti N et al. Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 2010: 23: 125.